NCT04014881: Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia. |
|
|
| Unknown status | 1 | 50 | RoW | Third-generation anti-CD123 CAR-T cells | Wuhan Union Hospital, China, Wuhan Bio-Raid Biotechnology Co., Ltd. | CD123+ Acute Myeloid Leukemia | 07/21 | 07/22 | | |
